A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab |
Lee, Sang-Kyu
(Translational Research Center for Protein Function Control, Yonsei University)
Cho, Yong-Hee (Translational Research Center for Protein Function Control, Yonsei University) Cha, Pu-Hyeon (Translational Research Center for Protein Function Control, Yonsei University) Yoon, Jeong-Soo (Translational Research Center for Protein Function Control, Yonsei University) Ro, Eun Ji (Translational Research Center for Protein Function Control, Yonsei University) Jeong, Woo-Jeong (Translational Research Center for Protein Function Control, Yonsei University) Park, Jieun (Translational Research Center for Protein Function Control, Yonsei University) Kim, Hyuntae (Translational Research Center for Protein Function Control, Yonsei University) Kim, Tae Il (Department of Internal Medicine and Institute of Gastroenterology, College of Medicine, Yonsei University) Min, Do Sik (Translational Research Center for Protein Function Control, Yonsei University) Han, Gyoonhee (Translational Research Center for Protein Function Control, Yonsei University) Choi, Kang-Yell (Translational Research Center for Protein Function Control, Yonsei University) |
1 | Cha, P. H. et al. Small-molecule binding of the axin RGS domain promotes beta-catenin and Ras degradation. Nat. Chem. Biol. 12, 593-600 (2016). DOI |
2 | Cho, Y. H. et al. KY1022, a small molecule destabilizing Ras via targeting the Wnt/beta-catenin pathway, inhibits development of metastatic colorectal cancer. Oncotarget 7, 81727-81740 (2016). |
3 | Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008). DOI |
4 | Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008). DOI |
5 | Lievre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374-379 (2008). DOI |
6 | Yun, J. et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325, 1555-1559 (2009). DOI |
7 | Shroyer, N. F. Tumor organoids fill the niche. Cell. Stem. Cell. 18, 686-687 (2016). DOI |
8 | Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990). DOI |
9 | Loeb, L. A., Loeb, K. R. & Anderson, J. P. Multiple mutations and cancer. Proc. Natl. Acad. Sci. USA 100, 776-781 (2003). DOI |
10 |
Moon, B.-S. et al. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/ |
11 | Crunkhorn, S. Anticancer drugs: Selectively targeting proteins for degradation. Nat. Rev. Drug Discov. 14, 459 (2015). |
12 | Downward, J. RAS synthetic lethal screens revisited: still seeking the elusive prize? Clin. Cancer Res. 15, 1802-1809 (2015). |
13 | Simanshu,D. K., Nissley, D. V. &McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17-33 (2017). DOI |
14 | Papke, B. & Der, C. J. Drugging RAS: know the enemy. Science 355, 1158-1163 (2017). DOI |
15 | Dang, C. V., Reddy, E. P., Shokat, K. M. & Soucek, L. Drugging the'undruggable'cancer targets. Nat. Rev. Cancer 17, 502-508 (2017). DOI |
16 | Grabocka, E. et al. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 25, 243-256 (2014). DOI |
17 | Horst, D. et al. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res. 72, 1547-1556 (2012). DOI |
18 | Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22 (2003). DOI |
19 | Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996). DOI |
20 | D'Abaco, G. M., Whitehead, R. H. & Burgess, A. W. Synergy between Apc min and an activated ras mutation is sufficient to induce colon carcinomas. Mol. Cell. Biol. 16, 884-891 (1996). DOI |
21 | Sansom, O. J. et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc. Natl Acad. Sci. USA 103, 14122-14127 (2006). DOI |
22 | Tan, X. et al. Epidermal growth factor receptor: a novel target of the Wnt/betacatenin pathway in liver. Gastroenterology 129, 285-302 (2005). DOI |
23 | Yun, M.-S., Kim, S.-E., Jeon, S. H., Lee, J.-S. & Choi, K.-Y. Both ERK andWnt/betacatenin pathways are involved in Wnt3a-induced proliferation. J. Cell Sci. 118 (Pt 2), 313-322 (2005). DOI |
24 | Park, K.-S. et al. APC inhibits ERK pathway activation and cellular proliferation induced by RAS. J. Cell Sci. 119(Pt 5), 819-827 (2006). DOI |
25 | Jeon, S. H. et al. Axin inhibits extracellular signal-regulated kinase pathway by Ras degradation via beta-catenin. J. Biol. Chem. 282, 14482-14492 (2007). DOI |
26 | Jeong, W. J. et al. Ras stabilization through aberrant activation of Wnt/betacatenin signaling promotes intestinal tumorigenesis. Sci. Signal. 5, ra30 (2012). |
27 | Kim, S. E. et al. H-Ras is degraded by Wnt/beta-catenin signaling via beta-TrCPmediated polyubiquitylation. J. Cell Sci. 122(Pt 6), 842-848 (2009). DOI |
28 |
Guturi, K. K. N. et al. Mechanism of |
29 | Gross, M. et al. Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res. 51, 1452-1459 (1991). |
30 |
Hu, T. & Li, C. Convergence between Wnt- |
31 | Radinsky, R. et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res. 1, 19-31 (1995). |
![]() |